Screening studies, along with the Cancer Genome Atlas (TCGA) database, have demonstrated that SPOP mutations represent an early event during disease development, and they are largely exclusive with the common ETS gene fusion events in prostate cancer, making SPOP-mutant tumors a distinct subgroup of prostate cancer (12). Here, SPOP is linked to prostate cancer.